ONO PHARMACEUTICAL CO.,LTD.

November 24, 2015

European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

THOUSAND OAKS, Calif.(November 19, 2015) --Amgen (NASDAQ: AMGN) announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Kyprolis is the first irreversible proteasome inhibitor approved in the European Union (EU) for use in combination treatment of patients with relapsed multiple myeloma.

For your further information, visit the link below to the website for press release distributed by Amgen.
http://www.amgen.com/media/news-releases/2015/11/european-commission-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma/

In Japan, ONO entered into an exclusive license agreement with Onyx, a subsidiary of Amgen, in September 2010 to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib (for injection) and oprozomib (orally administered) for all oncology indications. ONO submitted Manufacturing and Marketing Approval Application for carfilzomib for Injection "(ONO-7057)", to seek an indication for relapsed or refractory multiple myeloma in August 2015.

Contact
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp